Psyllium seed gum
CAS 8063-16-9
Psyllium seed gum (CAS 8063-16-9) is a pharmaceutical compound with 0 bioactivity targets and 3,397 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Psyllium seed gum is linked to DTXSID301057376 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Psyllium seed gum used for in pharmaceutical contexts?
Psyllium seed gum (CAS 8063-16-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Psyllium seed gum?
Psyllium seed gum has 3,397 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Condition aggravated, Drug ineffective, Feeling hot, Injection site erythema, Injection site mass. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Psyllium seed gum also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Plantago Ovata Husk Powder with EU status "permitted".
What clinical phase is Psyllium seed gum in?
No phase 1-4 clinical development badge is rendered for Psyllium seed gum because the matched compound identifier rows do not contain a max-phase value.